glp-1 inflammatory bowel disease Drugs: For Multiple Chronic Conditions Frontiers | GLP-1 and GLP-2

The authors state that in most cases of toxicity have been associated to formulations containing various ingredients, while GC has not been positively confirmed as the toxic agent

doi: 10.3389/fcimb.2023.1089374 Received 04 November 2022 Accepted 21 March 2023 Published 17 April 2023 Volume 13 - 2023 Edited by Seung-Hak Cho, Korea National Institute of Health, Republic of Korea Reviewed by Kurt Schesser, University of Miami, United States

The views expressed are those of the author(s) and not necessarily those of the any of the funders, the NHS, the NIHR or the Department of Health

Large medical references do not classify escitalopram as an addictive drug

This has given rise to research interest in DSIP nasal spray

In another study, Thangaraj et al